Eledon Reports Results of Tegoprubart in P-IIa Trial Demonstrated Safety, Target Engagement, and Biomarker Response for ALS
Shots:
- The P-IIa trial evaluates tegoprubart in 54 patients with ALS at 13 sites in the US & Canada. The trial met its 1EPs of safety & tolerability with no drug-related serious AEs, ADAs were of low titer and did not impact tegoprubart drug levels
- At doses of 4 & 8mg/kg, target engagement was dose-dependent, ALS associated pro-inflammatory biomarkers were observed and significantly reduced in a dose dependent manner, pro-inflammatory biomarkers reduced included biomarkers also associated with IgAN and kidney allograft transplant rejection
- Additionally, target engagement & pro-inflammatory biomarker reduction were linked to a trend in disease progression slowing over ALS PRO-ACT database
Ref: Eledon | Image: Eledon
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
